The DOI matches its Crossref record.
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Open accessAbstract
Abstract Learning Objectives After completing this course, the reader will be able to:Explain the molecular biology of epidermal growth factor receptor (EGFR) function in malignant cells.Recognize the relationships between and functions of the erbB family of related cell membrane receptors.Describe the current status of clinical strategies to inhibit EGFR function in malignant cells. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com There is a need for new, selective anticancer agents that differentiate between malignant and nonmalignant cells. The benefits of such agents would include a higher therapeutic index and lower toxicity than conventional therapies. Although expressed in nonmalignant cells, the epidermal growth factor receptor (EGFR) is highly expressed in a variety of tumors, and its expression correlates with poor response to treatment, disease progression, and poor survival. Evidence for a role for the EGFR in the inhibition and pathogenesis of various cancers has led to the rational design and development of agents that selectively target this receptor. Activation of the EGFR signaling pathway in cancer cells has been linked with increased cell proliferation, angiogenesis, and metastasis, and decreased apoptosis. Preclinical data show that anti-EGFR therapies can inhibit these effects in vitro and in vivo. In addition, preclinical data confirm that many such agents have the potential to increase the effectiveness of current cytotoxic agents. Following accelerated drug development programs, phase III trials are now under way for a number of EGFR-targeted therapies, including the monoclonal antibody IMC-C225 and the EGFR-tyrosine kinase inhibitors ZD1839 (IressaTM) and OSI-774. Thus, the rationale for EGFR-targeted approaches to cancer treatment is apparent and now well established, and there is increasing evidence that they may represent a significant contribution to cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chromosome aberrations in solid tumors
Albertson, D. G., Collins, C., McCormick, F., & Gray, J. W. (2003) · Nature Genetics · doi:10.1038/ng1215 · Cited by 812
Signaling through the epidermal growth factor receptor during the development of malignancy
Grandis, J. R., & Sok, J. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.01.002 · Cited by 320
Vincenzi, B., Santini, D., Russo, A., Gavasci, M., Battistoni, F., Dicuonzo, G., Rocci, L., Rosaria, V. M., Gebbia, N., & Tonini, G. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.319 · Cited by 38
Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1208 · Cited by 34
In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., & Castorina, S. (2014) · Cell Proliferation · doi:10.1111/cpr.12125 · Cited by 27
Metadata
- Authors
- Baselga, J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-15
- Volume
- 7
- Issue
- 90004
- Pages
- 2-8
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2169332099
- Cited by
- 510
- References
- 0
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. https://app.cochat.ai/papers/10.1634/theoncologist.7-2004-2
- The paper
- Baselga, J. (2002). Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. The Oncologist. https://doi.org/10.1634/theoncologist.7-2004-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
